Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Current Leases (2021 - 2025)

Capricor Therapeutics has reported Current Leases over the past 5 years, most recently at $202376.0 for Q4 2025.

  • Quarterly results put Current Leases at $202376.0 for Q4 2025, down 75.76% from a year ago — trailing twelve months through Dec 2025 was $202376.0 (down 75.76% YoY), and the annual figure for FY2025 was $202376.0, down 75.76%.
  • Current Leases for Q4 2025 was $202376.0 at Capricor Therapeutics, up from $120094.0 in the prior quarter.
  • Over the last five years, Current Leases for CAPR hit a ceiling of $849505.0 in Q2 2025 and a floor of $120094.0 in Q3 2025.
  • Median Current Leases over the past 5 years was $707425.0 (2023), compared with a mean of $645984.9.
  • Biggest five-year swings in Current Leases: surged 63.31% in 2022 and later crashed 85.24% in 2025.
  • Capricor Therapeutics' Current Leases stood at $417632.0 in 2021, then skyrocketed by 63.31% to $682039.0 in 2022, then increased by 9.83% to $749112.0 in 2023, then grew by 11.44% to $834799.0 in 2024, then crashed by 75.76% to $202376.0 in 2025.
  • The last three reported values for Current Leases were $202376.0 (Q4 2025), $120094.0 (Q3 2025), and $849505.0 (Q2 2025) per Business Quant data.